December 21, 2016

Dear Eye Care Professional:

2016 has been an exceptional year for Bausch + Lomb and the growth of our business as we have introduced our latest technologies to surgical centers, which include new product developments and access to new products through our acquisition and distribution programs. As we look to the year ahead, we are incredibly excited about the future of our business with the acceleration of new product introductions in each of our surgical categories as a result of the continuous investment we are making in ophthalmology R&D.

Thanks to the support and partnership of you, our customers, we’ve made multiple enhancements to our already robust portfolio, by bringing to market more than 10 new product innovations this year – an unprecedented number for our organization.

Since we announced the exclusive distribution of the iSert® line of preloaded intraocular lenses (IOLs) from HOYA, we have seen tremendous growth in sales of this leading optic and innovative injector design. We also announced a groundbreaking partnership with IBM to develop applications that will enhance the surgical experience and improve overall operational efficiency. We look forward to sharing more about this project soon, as we are making significant progress and engaging surgeons every step of the way to ensure that the end product meets and exceeds their needs.

In retina, we expanded our commitment by creating a dedicated R&D team focused solely on this dynamic space, and fast-tracking innovations such as the Illuminated Directional Laser Probe, the 27-gauge Directional Laser Probe and the first and only 27-gauge Diamond Dusted Membrane Scraper.

As we head into 2017, we look forward to continuing our tremendous momentum to grow our commitment to advancing innovation and patient outcomes through the introduction of technologies such as the Stellaris Elite™ platform. Stellaris Elite™ is our innovative next generation model that will offer more than 14 innovations and features for both vitreoretinal and cataract surgery, which we anticipate launching in the first half of the year. We will also launch two new IOL optic designs, a new IOL material, two new injectors, and six product line enhancements to our IOL portfolio. In addition, we are expecting a FDA decision on our new capsular tension ring, as well as our new software and indications for our VICTUS® femtosecond laser for cataract and refractive procedures.

We are excited to bring these new developments to your operating room in the New Year and explore how they can change the way you provide advanced care and positive outcomes for your patients. As always, we are grateful for the unwavering support and partnership of you, our customers, and look forward to strengthening our relationship with you in 2017.

Please reach out to me at any time at Chuck.Hess@bausch.com should you have any questions, concerns or ideas to share. In the meantime, on behalf of the entire Bausch + Lomb team, I want to wish you and your families a beautiful holiday season, and continued success and happiness in the New Year.

Best regards,

 

Chuck Hess                                                                                            

Vice President & General Manager                                                      
U.S. Surgical, Bausch + Lomb      

Stellaris, Stellaris Elite and VICTUS are trademarks of Bausch & Lomb Incorporated or its affiliates.
iSert is a trademark of Hoya Surgical Optics GmbH.
© 2016 Bausch & Lomb Incorporated. H230.0019.USA.16